These results indicate that the MCH-MCHR1 system works to accumulate energy in the body; therefore, MCH-receptor antagonists are currently believed to be attractive therapeutic targets for the treatment of obesity. The gene discussed is PMCH; the disease is obesity due to melanocortin 4 receptor deficiency.